Krystal Biotech, Inc. (KRYS)
After hours:
| Previous Close | 155.68 |
| Open | 156.28 |
| Bid | 156.68 x 100 |
| Ask | 157.40 x 100 |
| Day's Range | 153.79 - 157.59 |
| 52 Week Range | 82.09 - 189.97 |
| Volume | |
| Avg. Volume | 393,853 |
| Market Cap | 4.473B |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | 402.26 |
| EPS (TTM) | 0.39 |
| Earnings Date | May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 188.50 |
GlobeNewswireKrystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2024 financial results on Monday, May 6, 2024, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, May 6, 2024, to discuss the financial results and provide a business update. Investors and the general public can access the l
ZacksDown -7.21% in 4 Weeks, Here's Why Krystal Biotech (KRYS) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Krystal Biotech (KRYS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- GlobeNewswire
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
• Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the first patient was dosed in its Phase 1 clinical trial (KYANITE-1) evaluating inhaled KB707, a modified HSV-1 vector designed to deliver genes encoding both human interleukin-12 (IL-12) and interleukin-2 (IL-2) to the lung, for the treatment of patients with
